
    
      A Phase 1 randomized, vehicle-controlled, blinded study to assess the safety, tolerability,
      and PK of single ascending doses of inhaled TLC19 (Hydroxychloroquine Liposome Inhalation
      Suspension) in healthy volunteer subjects. Three dose levels will be assessed in sequential
      cohorts, with 2 mL, 4 mL, and 6 mL. Total of approximately 30 subjects will be randomized in
      the study in 3 cohorts. Subjects will be enrolled and randomized to receiving either TLC19 or
      TLC 19 Vehicle.

      Drug Administration: Blinded study medication will be administered through inhalation via a
      portable vibration mesh nebulizer.
    
  